Literature DB >> 26629270

Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2015        PMID： 26629270      PMCID： PMC4665047     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  16 in total

Review 1.  Polycythemia vera: myths, mechanisms, and management.

Authors:  Jerry L Spivak
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

2.  Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

Authors:  Francesco Passamonti; Elisa Rumi; Daniela Pietra; Matteo G Della Porta; Emanuela Boveri; Cristiana Pascutto; Laura Vanelli; Luca Arcaini; Sara Burcheri; Luca Malcovati; Mario Lazzarino; Mario Cazzola
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

Review 3.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

Review 4.  Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Authors:  A M Vannucchi; E Antonioli; P Guglielmelli; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2008-05-22       Impact factor: 11.528

5.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

6.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

Review 7.  Thrombotic disease in the myeloproliferative neoplasms.

Authors:  Anna Falanga; Marina Marchetti
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

Review 8.  Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.

Authors:  Ayalew Tefferi
Journal:  Am J Hematol       Date:  2011-03       Impact factor: 10.047

Review 9.  From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera.

Authors:  S M Fruchtman; K Mack; M E Kaplan; P Peterson; P D Berk; L R Wasserman
Journal:  Semin Hematol       Date:  1997-01       Impact factor: 3.851

10.  Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.

Authors:  A Weinfeld; B Swolin; J Westin
Journal:  Eur J Haematol       Date:  1994-03       Impact factor: 2.997
View more
  14 in total

Review 1.  Co-dependencies in the tumor immune microenvironment.

Authors:  Peiwen Chen; Prasenjit Dey
Journal:  Oncogene       Date:  2022-07-11       Impact factor: 8.756

2.  Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.

Authors:  Pilar Blanco Lobo; Paloma Guisado-Hernández; Isabel Villaoslada; Beatriz de Felipe; Carmen Carreras; Hector Rodriguez; Begoña Carazo-Gallego; Ana Méndez-Echevarria; José Manuel Lucena; Pilar Ortiz Aljaro; María José Castro; José Francisco Noguera-Uclés; Joshua D Milner; Katelyn McCann; Ofer Zimmerman; Alexandra F Freeman; Michail S Lionakis; Steven M Holland; Olaf Neth; Peter Olbrich
Journal:  J Clin Immunol       Date:  2022-05-04       Impact factor: 8.542

3.  Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.

Authors:  Marissa A Zarakas; Jigar V Desai; Georgios Chamilos; Michail S Lionakis
Journal:  Curr Fungal Infect Rep       Date:  2019-07-05

4.  New and Emerging Therapies for Pediatric Atopic Dermatitis.

Authors:  Henry L Nguyen; Katelyn R Anderson; Megha M Tollefson
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.930

5.  Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.

Authors:  Qian Li; Botao Li; Liangding Hu; Hongmei Ning; Min Jiang; Danhong Wang; Tingting Liu; Bin Zhang; Hu Chen
Journal:  Oncotarget       Date:  2017-05-23

Review 6.  Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment.

Authors:  Elizabeth A Comen; Robert L Bowman; Maria Kleppe
Journal:  Front Cell Dev Biol       Date:  2018-06-12

7.  A photo-distributed papulopustular eruption and multiple squamous cell carcinomas in a patient on ruxolitinib.

Authors:  Urmi Khanna; Veronica Richardson; Elizabeth Hexner; Cuong V Nguyen; Rosalie Elenitsas; Misha Rosenbach
Journal:  JAAD Case Rep       Date:  2019-10-22

8.  Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice.

Authors:  Han-Chung Lee; Hamizun Hamzah; Pike-See Cheah; King-Hwa Ling; Melody Pui-Yee Leong; Hadri Md Yusof; Omar Habib; Shahidee Zainal Abidin; Eryse Amira Seth; Siong-Meng Lim; Sharmili Vidyadaran; Mohamad Aris Mohd Moklas; Maizaton Atmadini Abdullah; Norshariza Nordin; Zurina Hassan
Journal:  Sci Rep       Date:  2021-02-15       Impact factor: 4.379

Review 9.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

10.  Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib.

Authors:  Ramy M Hanna; Maham Khalid; Lama Abd El-Nour; Umut Selamet
Journal:  Antibiotics (Basel)       Date:  2019-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.